Company Encyclopedia
View More
name
JUMPCAN
600566.SH
Hubei Jumpcan Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of drugs in China. The company offers Chinese traditional and Western medicines, daily use chemicals, and medicine health products in various formulations. Its products are used in the areas of detoxification, digestive system, pediatric, respiratory system, nervous system, anti-infection, cardiovascular, narcotic analgesic, nutrition, musculoskeletal, hemostasis, gynecology, pneumology, gastroenterology, and geriatrics.
3.095 T
600566.SHMarket value -Rank by Market Cap -/-

Financial Score

27/12/2025 Update
C
PharmaceuticalsIndustry
Industry Ranking87/223
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreA
    • ROE11.84%B
    • Profit Margin26.88%A
    • Gross Margin77.77%A
  • Growth ScoreE
    • Revenue YoY-31.15%E
    • Net Profit YoY-40.64%D
    • Total Assets YoY-8.92%E
    • Net Assets YoY-1.68%D
  • Cash ScoreD
    • Cash Flow Margin372.08%C
    • OCF YoY-31.15%E
  • Operating ScoreD
    • Turnover0.35D
  • Debt ScoreA
    • Gearing Ratio16.18%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Jumpcan Pharmaceutical's Q3 Profit Drops 47%, Revenue Falls 33%

    Jumpcan Pharmaceutical's Q3 Profit Drops 47%, Revenue Falls 33%

    marketscreener·
    SH
    600566
    +0.19%
    marketscreener·
    SH
    600566
    +0.19%

    Jumpcan Pharma Gets Registration Certificate for Lidocaine Cataplasms

    (MT Newswires) -- Hubei Jumpcan Pharmaceutical (SHA:600566), through unit Shaanxi Dongke Pharmaceutical, obtained a drug registration certificate from the Chinese drug administration for its lidocaine cataplasms, according to a Shanghai bourse filing on Wednesday. The product is an amide local anesthetic that stabilizes nerve cell membranes. The certificate is valid until Sept. 8, 2030, the Chinese drug maker said.

    marketscreener·
    SH
    600566
    +0.19%
    marketscreener·
    SH
    600566
    +0.19%

    JUMPCAN's subsidiary has obtained the drug registration certificate for lidocaine gel patches

    According to the Zhitong Finance APP, JUMPCAN announced that its wholly-owned subsidiary Shaanxi Dongke Pharmaceutical Co., Ltd. (referred to as "Shaanxi Dongke") has received the drug registration certificate for lidocaine gel patch approved and issued by the National Medical Products Administration. Lidocaine is an amide-type local anesthetic that stabilizes nerve cell membranes by inhibiting the ion channels required for the generation and conduction of nerve impulses

    Zhitong·
    SH
    600566
    +0.19%
    Zhitong·
    SH
    600566
    +0.19%

    Zhitong A-share lock-up release overview | September 8

    On September 8th, 21 listed companies will have their restricted shares unlocked, with a total market value of approximately 35.072 billion yuan. The unlocking situation includes several companies such as Xizang Mineral, FEIDA ENVIRO, and JUMPCAN, involving equity incentives and the allocation of additional A-shares to original shareholders. The specific number of unlocked shares ranges from 17,300 to 2.234 billion, covering multiple industries

    Zhitong·
    SH
    600526
    -0.37%
    SZ
    000762
    +2.19%
    SH
    600566
    +0.19%
    Zhitong·
    SH
    600526
    -0.37%
    SZ
    000762
    +2.19%
    SH
    600566
    +0.19%

    Cao Fei intends to acquire JUMPCAN, and the supervision situation in the second quarter has been good

    Cao Fei acquired the equity of JUMPCAN on June 11, 2025, triggering the obligation for a tender offer, with the acquisition period ending on July 17. The pre-offer shares amounted to 16,300 shares, accounting for 0.0018% of the total share capital. The settlement transfer was completed on August 1, with Cao Fei and his concerted actors controlling 61.15% of the shares, meeting the listing conditions. During the continuous supervision period, the acquirer and the listed company operated in a standardized manner, without making significant adjustments to the main business, assets, or personnel, and JUMPCAN had no violations regarding guarantees or loans

    Zhitong·
    SH
    600566
    +0.19%
    Zhitong·
    SH
    600566
    +0.19%
    © 2025 Longbridge｜Disclaimer